Votrient (Pazopanib)

Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of adults with:

• advanced renal cell carcinoma (RCC).
• advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

Limitations of Use: The efficacy of this therapeutic drug for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors (GISTs) has not been demonstrated.

Recommended Dosage:
The recommended dosage of Pazopanib is 800 mg (four 200 mg tablets) orally once daily without food (at least 1 hour before or 2 hours after a meal) until there is evidence of disease progression or unacceptable toxicity. The dosage can be modified for hepatic impairment and in patients taking certain concomitant medicines. Swallow tablets whole without crushing, as this may be responsible for increasing the rate of absorption and affecting systemic exposure.
In case a dose of Pazopanib is missed/skipped, it should not be taken if it is < 12 hours until the next scheduled dose.

• Pazopanib treatment can result in severe liver complications. Summarize all necessary tests before starting treatment and keep checking throughout. It is necessary to stop all treatment if there is an increase of 3 times the norm of ALT alongside an elevation of bilirubin. Be extra careful in patients with pre-existing diseases of the liver or hepatic insufficiency.
• Torsades de pointes may occur with Pazopanib 200 mg usage due to prolongation of the QT interval. Monitor ECG closely in patients with a history of problems related to the QT interval. Avoid using on patients with electrolyte derangement and those under medications that are known to increase the QT interval.
• Congestive heart failure and decreased left ventricular function may occur with Pazopanib treatment. Make an assessment of the patient’s cardiac function before treating, especially if there is a history of heart conditions. Only perform treatment upon signs of heart failure. Control blood pressure and heart alongside these during treatment.
• Serious bleeding, including fatal hemorrhages, may occur. Use with careful attention on patients who have an increased risk of bleeding, those who have recently undergone surgery. Monitor for signs of bleeding, and if serious bleeding occurs doctor should stop all treatments immediately.
• Use with caution on patients who have a history of having strokes and heart attacks, as Pazopanib is associated with strong thromboembolic events. If any signs of arterial thromboembolic events show up, the doctor should stop these treatments right away. Otherwise, regular check-ups of cardiovascular health should be done while treating.
• Deep vein thrombosis (DVT) and pulmonary embolism may occur. Patients need to be evaluated for leg swelling or difficulty in breathing. If serious venous thromboembolic incidents happen during care, treatment should be stopped.
• Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, may occur. Discontinue treatment with Pazopanib permanently in case TMA is diagnosed. Quick recognition and supportive treatment are important for recovery.
• Pazopanib may cause life-threatening issues such as gastrointestinal perforation and fistula formation. Patients facing these symptoms should be treated for abdominal discomfort as well as inflammation indicators. Therapy should cease if gastrointestinal perforation is found.
• Cases of interstitial lung disease and pneumonitis, some leading to death, have been recognized too. Advanced imaging alongside suitable management might be given after the necessary confirmation. Therapy must stop if PMD-like coughs or trouble breathing tend to worsen, alongside other symptoms.
• Pazopanib can cause hypertension, and obese patients are more prone to it. Regular monitoring throughout the treatment will help tackle these issues. Medication to fight hypertension, along with treatment, has to change during the treatment. Under or stopping Pazopanib is mandatory if hypertension reaches uncontrollable extremes.
• Tumor lysis syndrome (TLS), a potentially fatal condition, may occur. Patients with high tumor burden are at higher risk. Monitor closely and ensure adequate hydration. Start appropriate prophylactic measures and stop in case TLS develops.
• Avoid using Pazopanib 200 mg in pregnant patients as it can cause harm to the fetus. Its use is contraindicated during pregnancy. Women of childbearing age should utilize effective birth control both during and for some time after treatment. Counsel patients on possible risks to fetal development.
• There is no information available regarding the excretion of Pazopanib in breast milk. Due to its potentially serious side effects on the health of young children, breastfeeding is contraindicated while on treatment and for some time after the last dose of Pazopanib.

What documents are required to import VOTRIENT to India?

VOTRIENT (pazopanib) tablets can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is VOTRIENT available in India?

VOTRIENT (pazopanib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Votrient in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

VOTRIENT can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of VOTRIENT (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Votrient 200 mg tablet price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source VOTRIENT (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Votrient®?

Pazopanib is the Generic Name for the trade name drug Votrient®.

What is the Manufacturer's Name of Votrient®?

Votrient® is manufactured by GlaxoSmithKline.

What is the dosage and form of Votrient® supplied?

Votrient is supplied in Tablets: 200 mg for oral administration.

What are the most common side effects of Votrient® 200 mg tablets?

The most common side effects of Votrient® in patients with:

• RCC: diarrhea, hypertension, nausea, anorexia, hair color changes (depigmentation), and vomiting.
• STS: fatigue, diarrhea, hypertension, decreased weight, decreased appetite, dyspnea,vomiting, hair color changes, tumor pain, musculoskeletal pain, headache, dysgeusia, nausea, and skin hypopigmentation

How much does Votrient® 200 mg Tablet cost in India?

Prices of Votrient tablets may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Votrient 200 mg tablet cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Votrient® 200 mg Tablets be available in SAARC countries?

Apart from Gulf countries, Votrient® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Votrient® tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Votrient® 200 mg tablets online in India?

Yes, one can buy Votrient 200 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Votrient® tablets through legal channels.

What are the storage conditions of Votrient® 200 mg Tablets?

Store pazopanib tablets at 20 to 25°C (68 to 77°F), excursions permitted between 15 and 30°C (59 and 86°F).